1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance
2.1. Total Epidemiology Share (%) Distribution of ALD in 2017
2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview
3.1. Introduction
3.2. Clinical aspects of ALD
3.3. Causes of ALD
3.4. Inheritance pattern of ALD
3.5. ALD-Symptoms
3.6. Pathogenesis and Pathophysiology of ALD
3.7. Diagnosis
3.7.1. ALD Newborn Screening
3.7.2. Tools for evaluating Cerebral ALD
3.7.3. Diagnostic algorithm
3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Epidemiology Methodology
4.3. KOL Views
4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix
8.1. Bibliography
8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance
2.1. Total Epidemiology Share (%) Distribution of ALD in 2017
2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview
3.1. Introduction
3.2. Clinical aspects of ALD
3.3. Causes of ALD
3.4. Inheritance pattern of ALD
3.5. ALD-Symptoms
3.6. Pathogenesis and Pathophysiology of ALD
3.7. Diagnosis
3.7.1. ALD Newborn Screening
3.7.2. Tools for evaluating Cerebral ALD
3.7.3. Diagnostic algorithm
3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Epidemiology Methodology
4.3. KOL Views
4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix
8.1. Bibliography
8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

1. Key Insights

2. Adrenoleukodystrophy (ALD): Epidemiology Overview at a Glance
2.1. Total Epidemiology Share (%) Distribution of ALD in 2017
2.2. Total Epidemiology Share (%) Distribution of ALD in 2030

3. Adrenoleukodystrophy: Disease Background and Overview
3.1. Introduction
3.2. Clinical aspects of ALD
3.3. Causes of ALD
3.4. Inheritance pattern of ALD
3.5. ALD-Symptoms
3.6. Pathogenesis and Pathophysiology of ALD
3.7. Diagnosis
3.7.1. ALD Newborn Screening
3.7.2. Tools for evaluating Cerebral ALD
3.7.3. Diagnostic algorithm
3.7.4. HSCT and presymptomatic diagnosis of ALD in Japan

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Epidemiology Methodology
4.3. KOL Views
4.4. Total Prevalent Population of Adrenoleukodystrophy in the 7MM

5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalent Population of Adrenoleukodystrophy (ALD) in the United States
5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United States
5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United States
5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United States

6. EU5 Epidemiology
6.1. Germany Epidemiology
6.1.1. Assumptions and Rationale
6.1.2. Total Prevalent Population of Adrenoleukodystrophy in Germany
6.1.3. Gender-specific Prevalence of Adrenoleukodystrophy in Germany
6.1.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany
6.1.5. Type-specific Diagnosed Prevalence of ALD in males in Germany
6.2. France Epidemiology
6.2.1. Assumptions and rationale
6.2.2. Total Prevalent Population of Adrenoleukodystrophy in France
6.2.3. Gender-specific Prevalence of Adrenoleukodystrophy in France
6.2.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France
6.2.5. Type-specific Diagnosed Prevalence of ALD in Males in France
6.3. Italy Epidemiology
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalent Population of Adrenoleukodystrophy in Italy
6.3.3. Gender-specific Prevalence of Adrenoleukodystrophy in Italy
6.3.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy
6.3.5. Type-specific Diagnosed Prevalence of ALD in Males in Italy
6.4. Spain Epidemiology
6.4.1. Assumptions and Rationale
6.4.2. Total Prevalent Population of Adrenoleukodystrophy in Spain
6.4.3. Gender-specific Prevalence of Adrenoleukodystrophy in Spain
6.4.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain
6.4.5. Type-specific Diagnosed Prevalence of ALD in Males in Spain
6.5. United Kingdom Epidemiology
6.5.1. Assumptions and Rationale
6.5.2. Total Prevalent Population of Adrenoleukodystrophy in the United Kingdom
6.5.3. Gender-specific Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the United Kingdom
6.5.5. Type-specific Diagnosed Prevalence of ALD in Males in the United Kingdom

7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Population of Adrenoleukodystrophy in Japan
7.3. Gender-specific Prevalence of Adrenoleukodystrophy in Japan
7.4. Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan
7.5. Type-specific Diagnosed Prevalence of ALD in Males in Japan

8. Appendix
8.1. Bibliography
8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables
Table 1 ALD Phenotypes in Males
Table 2 Phenotype in Female ALD carriers
Table 3 The ALD Phenotypes
Table 4 MRI Severity Scale
Table 5 MRI Severity Rating
Table 6 Neurological Function Score (NFS Score)
Table 7 X-linked Adrenoleukodystrophy-Disability Rating Scale (ALD-DRS)
Table 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017–2030)
Table 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017–2030)
Table 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017–2030)
Table 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017–2030)
Table 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017–2030)
Table 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017–2030)
Table 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017–2030)
Table 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017–2030)
Table 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017–2030)
Table 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017–2030)
Table 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017–2030)
Table 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017–2030)
Table 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017–2030)
Table 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017–2030)
Table 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017–2030)
Table 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017–2030)
Table 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017–2030)
Table 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017–2030)
Table 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017–2030)
Table 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017–2030)
Table 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017–2030)
Table 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017–2030)
Table 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017–2030)
Table 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017–2030)
Table 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017–2030)
Table 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017–2030)
Table 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017–2030)
Table 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017–2030)
Table 36 Type-Specific Diagnosed Prevalence of ALD in Males Japan (2017–2030)

List of Figures
Figure 1 Evolution of Phenotypes in ALD
Figure 2 Clinical Spectrum of ALD
Figure 3 Inheritance spectrum of ALD
Figure 4 Pathogenesis of VLCFA
Figure 5 Principles of ALD 3-tier screening
Figure 6 Diagnostic algorithm for diagnosis of adrenoleukodystrophy
Figure 7 ALD Screening Decision Tree
Figure 8 Total Prevalent Population of Adrenoleukodystrophy in the 7MM (2017–2030)
Figure 9 Total Prevalent Population of Adrenoleukodystrophy in the US (2017–2030)
Figure 10 Gender-Specific Prevalence of Adrenoleukodystrophy in the US (2017–2030)
Figure 11 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in the US (2017–2030)
Figure 12 Type Specific Diagnosed Prevalence of ALD in males in the US (2017–2030)
Figure 13 Total Prevalent Population of Adrenoleukodystrophy in Germany (2017–2030)
Figure 14 Gender-specific Prevalence of Adrenoleukodystrophy in Germany (2017–2030)
Figure 15 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Germany (2017–2030)
Figure 16 Type-specific Diagnosed Prevalence of ALD in males in Germany (2017–2030)
Figure 17 Total Prevalent Population of Adrenoleukodystrophy in France (2017–2030)
Figure 18 Gender-specific Prevalence of Adrenoleukodystrophy in France (2017–2030)
Figure 19 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in France (2017–2030)
Figure 20 Type-specific Diagnosed Prevalence of ALD in Males in France (2017–2030)
Figure 21 Total Prevalent Population of Adrenoleukodystrophy in Italy (2017–2030)
Figure 22 Gender-specific Prevalence of Adrenoleukodystrophy in Italy (2017–2030)
Figure 23 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Italy (2017–2030)
Figure 24 Type-specific Diagnosed Prevalence of ALD in Males in Italy (2017–2030)
Figure 25 Total Prevalent Population of Adrenoleukodystrophy in Spain (2017–2030)
Figure 26 Gender-specific Prevalence of Adrenoleukodystrophy in Spain (2017–2030)
Figure 27 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in Spain (2017–2030)
Figure 28 Type-specific Diagnosed Prevalence of ALD in Males in Spain (2017–2030)
Figure 29 Total Prevalent Population of Adrenoleukodystrophy in the UK (2017–2030)
Figure 30 Gender-specific Prevalence of Adrenoleukodystrophy in the UK (2017–2030)
Figure 31 Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the UK (2017–2030)
Figure 32 Type-specific Diagnosed Prevalence of ALD in Males in the UK (2017–2030)
Figure 33 Total Prevalent Population of Adrenoleukodystrophy in Japan (2017–2030)
Figure 34 Gender-specific Prevalence of Adrenoleukodystrophy in Japan (2017–2030)
Figure 35 Gender-Specific Diagnosed Prevalence of Adrenoleukodystrophy in Japan (2017–2030)
Figure 36 Type-Specific Diagnosed Prevalence of ALD in Males in Japan (2017–2030)